Abstract: A photo resist layer is used to protect a dielectric layer and conductive elements embedded in the dielectric layer when patterning an etch stop layer underlying the dielectric layer. The photo resist layer may further be used to etch another dielectric layer underlying the etch stop layer, where etching the next dielectric layer exposes a contact, such as a gate contact. The bottom layer can be used to protect the conductive elements embedded in the dielectric layer from a wet etchant used to etch the etch stop layer.

Abstract: An electronic device is disclosed. The electronic device includes a system board and a first set of electronic devices disposed over the system board. Each of the first set of electronic devices comprises a processing unit and a carrier carrying the processing unit. The electronic device also includes a first interconnection structure electrically connected with the processing unit through the carrier and configured to receive a first power from a first power supply unit and to transmit the first power to the processing unit.

Abstract: The invention relates to a method for manufacturing sunglass lenses, and a sunglass lens. The method comprises the following steps: S1, manufacturing of a color powder sheet: a color powder is added to a color powder sheet base material in a corresponding proportion to manufacture a plain color powder sheet; and S2, manufacturing of a lens: the color powder sheet manufactured in S1 is fixed in a cavity of a lens mold, a molten colorless and transparent lens base material is injection-molded in the cavity of the lens mold and is then integrally combined with the color powder sheet in the cavity of the lens mold, and demolding is carried out after cooling, so that a sunglass lens is manufactured. The problem of chromatic aberration of existing sunglass lenses or scratches of films on the existing sunglass lenses is solved.

Abstract: The present invention provides a pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and a method for preparing the same; wherein said pharmaceutical composition comprises a therapeutically effective amount of Spirulina extract and a pharmaceutically acceptable carrier. The Spirulina extract used in the present invention is extracted at a low temperature by the following steps: (a) adding an organic Spirulina powder into a hypotonic buffer solution and mixed well to obtain a mixture; (b) freezing the mixture from step (a) overnight at a temperature lower than 0° C.; (c) thawing the mixture from step (b); (d) separating and purifying the mixture from step (c) by a separator, and collecting blue fractions; and (e) spray drying the blue fractions from step (d).

Abstract: Treatment of picornavirus infection by inhibiting miR-141 activity. Also disclosed herein are a method for identify miR-141 inhibitory compounds and a method for identifying a target viral infection to be treated by anti-miR-141 therapy.

Abstract: Treatment of picornavirus infection by inhibiting miR-141 activity. Also disclosed herein are a method for identify miR-141 inhibitory compounds and a method for identifying a target viral infection to be treated by anti-miR-141 therapy.

Abstract: The present invention provides a pharmaceutical composition for treating rotavirus and/or respiratory syncytial virus infection and a method for preparing the same; wherein said pharmaceutical composition comprises a therapeutically effective amount of Spirulina extract and a pharmaceutically acceptable carrier. The Spirulina extract used in the present invention is extracted at a low temperature by the following steps: (a) adding an organic Spirulina powder into a hypotonic buffer solution and mixed well to obtain a mixture; (b) freezing the mixture from step (a) overnight at a temperature lower than 0° C.; (c) thawing the mixture from step (b); (d) separating and purifying the mixture from step (c) by a separator, and collecting blue fractions; and (e) spray drying the blue fractions from step (d).

Abstract: Selective deglycosylation of HIV-1 envelope proteins enhances their ability to elicit a protective immune response in people. Glycosylation can reduce or prevent immunological recognition of envelope protein domains. Selective deglycosylation exposes these domains and improves the opportunity for a protective immune response. Deglycosylation which produces substantial conformational changes (as determined by loss of infectivity) should be avoided. Recombinant HIV-1 envelope glycoproteins are generated which have primary amino acid sequence mutation(s) in consensus sequence(s) for N-linked glycosylation (sugar attachment), so as to prevent glycosylation at that site(s). The position of such genetic deglycosylation is important and should be between the C terminus of gp120 and the Cys at the N-terminal side of the cysteine loop containing the hyper-variable region 3 (V3) (this Cys is generally positioned about at residue 296, counting from the N-terminus of gp120).